Taiwan-based JelloX Biotech Inc. is aiming to transform oncology diagnostics with its innovative AI and 3D digital pathology platform. First shared by CEO Dr. Yen-Yin Lin at the August 2024 Annual Meeting of the Japanese Society of Digital Pathology, the start-up’s approach promises to advance patient care by offering groundbreaking insights into tumor biology.
“Technological advancements and the recent surge in AI have reshaped the future of healthcare,” Dr. Lin said in a press-release. “3D pathology can offer at least 50 times more information than conventional 2D methods, enabling pathologists to better stratify and personalize treatments. This leads to improved prognosis, better quality of life, and more patient-centered care.”
An early adopter of the technology, JelloX has stated that 40% of oncological patients could benefit from AI-driven 3D imaging, particularly for cases where traditional methods prove insufficient. Cancer is one of the most complex conditions, characterized by immense variability between cases. The company’s approach can help pathologists overcome the limitations of conventional diagnostics by offering more actionable information tailored to each individual case.
This technology also expands treatment options: for example, patients previously excluded from immunotherapy based on undetected biomarker expressions, are now given a new hope of earlier treatment initiation. Precision diagnostics JelloX pursues not only allows pathologists to gain a holistic view of tumors, but enables them to reduce false negatives and timely provide the correct treatment. For patients, this means reduced risk of misdiagnoses, lower costs, and improved customized patient-care.
“The fight against cancer is not a one-on-one battle, so partnerships are crucial,” said Dr. Lin. JelloX is collaborating with the leading medical institutions and a diverse range of organizations to hone and enhance their robust AI-powered 3D pathology platform. To assist this effort, JelloX leverages their MetaLite® software, recently cleared by the US Food and Drug Administration.
This platform continues to grow, aiming to accelerate biomarker research, refine diagnostics, and support drug development. By integrating anonymized patient data and outcomes from samples, it will continuously improve, finding novel biomarkers and facilitating breakthroughs in cancer treatment.
